An observational longitudinal study investigating the prevalence of positive anti-PF4, hematologic parameters and to describe platelet activation profiles in a cohort of individuals who received the Ad26.COV2.S vaccine in Rio Janeiro, Brazil
Latest Information Update: 16 Jan 2023
At a glance
- Drugs Ad26.COV2 S (Primary)
- Indications COVID 2019 infections
- Focus Therapeutic Use
Most Recent Events
- 16 Jan 2023 New trial record
- 13 Dec 2022 Results presented at the 64th American Society of Hematology Annual Meeting and Exposition